Printer Friendly

Research and Markets: Market of Paclitaxel Injection in China.

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/f3da95/market_of_paclitax) has announced the addition of the "Market of Paclitaxel Injection in China" report to their offering.

Nowadays, paclitaxel injection has been widely used to cure cancers like non-small cell lung cancer, breast cancer, and ovarian cancer, etc. Besides, paclitaxel injection has become one of the best selling anticancer drugs in the world. The paclitaxel injection production values had reached USD67.21 million for China in 2009, accounting for 10% of total in world. China has become one of the most important consumption markets in the world.

Chinese paclitaxel injection industry has witnessed significant development from 2005-2009. On the one hands, since 2005, China's government has issued a series of policies related to China's pharmaceutical industry like healthcare reform. What they effect the paclitaxel injection industry? On the other hand, paclitaxel injection has become the second largest market share in natural anticancer drugs in China, thanks to its good clinical effect and less side effect. What is the current production and consumption situation in China?

For China paclitaxel injection manufacturers, active pharmaceutical ingredient (paclitaxel APIs) plays an important role for them expend. Owing to the forbidden for the develop of natural yew and the development for planting yew, price of APIs has declined gradually, thus pushing down the price of paclitaxel injection price and get less profit. Besides, by the end of Jun. 2010, Chinese government has adjusted export tax rebate rate of paclitaxel injection. How the paclitaxel APIs and paclitaxel injection manufactures replied for this change? In 2009, Sichuan Jiufeng Pharmaceutical Nowadays, paclitaxel injection has been widely used to cure cancers like non-small cell lung cancer, breast cancer, and ovarian cancer, etc. Besides, paclitaxel injection has become one of the best selling anticancer drugs in the world. The paclitaxel injection production values had reached USD67.21 million for China in 2009, accounting for 10% of total in world. China has become one of the most important consumption markets in the world.

Chinese paclitaxel injection industry has witnessed significant development from 2005-2009. On the one hands, since 2005, China's government has issued a series of policies related to China's pharmaceutical industry like healthcare reform. How do they influence the paclitaxel injection industry? On the other hand, paclitaxel injection has enjoyed the second largest market share in natural anticancer drugs in China, thanks to its good clinical effect and less side effect. What is the current production and consumption situation in China?

For China paclitaxel injection manufacturers, active pharmaceutical ingredient (paclitaxel APIs) plays an important role for them expend. Owing to the increasing cultivated planting yew, price of APIs has declined gradually, thus pushing down the price of paclitaxel injection price. Besides, by the end of Jun. 2010, Chinese government has adjusted export tax rebate rate of paclitaxel injection. How did the paclitaxel APIs and paclitaxel injection manufacturers respond to this change? In 2009, Sichuan Jiufeng Pharmaceutical Co., Ltd. (Sichuan Jiufeng), the largest producer of paclitaxel injection in China, has increased its output of paclitaxel injection greatly because of the great demand, and then what is the performance of Sichuan Jiufeng in 2010?

What's more, paclitaxel injection has to get into hospitals through the pharmaceutical distribution companies and medicine bidding and purchasing platforms. How do the pharmaceutical distribution companies distribute the paclitaxel injection, and how does the medicine bidding and purchase platforms for paclitaxel injection are operated?

Besides the aspects mentioned above, what is the production distribution of paclitaxel APIs? What is the development trend of China's paclitaxel injection? The authors have carried out in-depth research and analysis on each active producer, as well as the whole industry to figure out these questions.

In this report, you can obtain info about:

* Production distribution of paclitaxel APIs

* General situation of paclitaxel injection production and its manufacturers

* Top 2 pharmaceutical distribution companies in China

* Medicine bidding and purchasing platforms

* Import and export paclitaxel injection analysis, as well as paclitaxel APIs export analysis

* Consumption situation of paclitaxel injection

* Government policy for paclitaxel injection and quality standards of paclitaxel injection

* circulation model of paclitaxel injection in China

With the information covered in the report, readers can see the general production and consumption situation, circulation model, as well as APIs supply situation for China paclitaxel injection manufacturers in China, which are beneficial for the investors decision making.

Key Topics Covered:

I Development of policy environment for paclitaxel injection in China

II Production of paclitaxel injection in China

III Production of paclitaxel APIs in China

IV China's paclitaxel injection distribution model

V China's medicine bidding and purchasing platform

VI Consumption of paclitaxel injection in China

VII Import and export situation in 2009

VIII Resource of yew in China

IX Profile of major manufacturers of paclitaxel injection in China

Companies Mentioned:

* Sichuan Jiufeng Pharmaceutical Co., Ltd.

* Chongqing Taiji Industry Group Co., Ltd.

* Hainan Haiyao Joint-stock Co., Ltd.

* Hainan Quanxing Yaoye Co., Ltd.

* Zhejiang Hisun Pharmaceutical Co., Ltd.

For more information visit http://www.researchandmarkets.com/research/f3da95/market_of_paclitax
COPYRIGHT 2010 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 20, 2010
Words:952
Previous Article:Panasonic to Strengthen PDP Production in China.
Next Article:Research and Markets: the Electric Car Report (2nd Edition) 2010 Examines the Market Drivers and Barriers and the Enabling Technologies That Are...
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters